The 8-Week Vitamin K2 Protocol: MK-4 vs MK-7 for Bone, Heart, and Performance
Why Timing and Sequencing Matter
Most people treat Vitamin K2 like a single compound. It isn't. MK-4 and MK-7 are structurally different molecules with different half-lives, different tissue affinities, and different clinical evidence behind them. Taking the wrong form for your goal isn't just suboptimal, it may mean you're getting none of the benefit you're after.
90-second summary
Read the transcript
MK-4 vs MK-7: which K2 form do you actually need? Most people treat Vitamin K2 like a single compound, but MK-4 and MK-7 are structurally different molecules with different half-lives and different targets in the body. Taking the wrong form for your goal could mean you are getting none of the benefit you are after. Here is how to think about it. MK-4 acts fast but clears your body within 24 hours. That speed makes it useful for rapid osteocalcin activation in bone and brain tissue, but it requires higher doses and split dosing to stay effective. MK-7 builds steady plasma levels with once-daily dosing. Its 72-hour half-life means a single 100 microgram dose maintains meaningful blood concentrations around the clock, which is why the clinical evidence for cardiovascular and systemic bone support is stronger with MK-7. Both forms together cover bone, arteries, and tissue health. The 8-week protocol in this article starts with a Vitamin D3 and MK-7 foundation in weeks one and two, adds MK-4 in week three for tissue-specific activation, runs both concurrently through week six, then reassesses based on your primary goal. A few things to get right along the way: always take K2 with a fat-containing meal, never skip D3, and if you are on warfarin, talk to your doctor before starting. Read the full 8-week protocol at Elm and Rye to build your complete K2 stack.
The sequencing matters for another reason: K2 works almost entirely through activation of two proteins, osteocalcin (which pulls calcium into bone) and Matrix Gla Protein (MGP) (which prevents calcium from depositing in arterial walls). Both require K2 to carboxylate them into their active state. But MK-4 reaches peak plasma concentration within hours and clears the body within 24 hours. MK-7 has a half-life of roughly 72 hours, producing stable, sustained plasma levels with once-daily dosing. That difference drives everything about how you should use each form.
K2 also doesn't work in isolation. It depends on Vitamin D3 to upregulate osteocalcin and MGP production in the first place. Without adequate D3, you're activating proteins that haven't been produced in sufficient quantity. That's why pairing these two is standard in bone-health research, and why I structure the protocol below to address D3 status first. If you're not already supplementing D3, read through the Elm & Rye Vitamin D3 formulation details before starting week one.
The Protocol
| Phase | Week | Compound | Dose | Timing | Goal |
|---|---|---|---|---|---|
| Foundation | 1-2 | Vitamin D3 + MK-7 | D3: 2,000-5,000 IU / MK-7: 100 mcg | With largest fat-containing meal | Establish D3 baseline, begin MGP carboxylation |
| Foundation | 1-2 | Magnesium Glycinate | 200-400 mg | Evening | Support D3 conversion to active form |
| Activation | 3-4 | MK-7 (continue) + add MK-4 | MK-7: 100 mcg / MK-4: 1,000-1,500 mcg | MK-7 with lunch, MK-4 split AM and PM | MK-4 for rapid osteocalcin activation in bone and brain tissue |
| Optimization | 5-6 | MK-7 (continue) + MK-4 (continue) | Same as Phase 2 | Same as Phase 2 | Sustained arterial MGP activation + bone mineral density signaling |
| Consolidation | 7-8 | Reassess: MK-7 alone or maintain dual | MK-7: 100-200 mcg | With dinner | Long-term maintenance dosing based on goal |
Note: MK-4 at doses below 500 mcg shows minimal clinical effect in human trials. The 1,000-1,500 mcg range reflects the dosing used in Japanese clinical research on bone density. MK-7 at 100 mcg daily is the threshold shown in a 2013 study published in Osteoporosis International to significantly improve carboxylated osteocalcin levels in postmenopausal women.
What to Expect Week by Week
Weeks 1-2: Foundation
You won't feel anything dramatic here, and that's expected. The goal is correcting D3 insufficiency, which affects how much osteocalcin and MGP your body is producing. MK-7's 72-hour half-life means plasma levels reach a meaningful steady state by day 10-14. Most people with suboptimal D3 status (common in San Francisco, where overcast skies from June through August suppress UV-B synthesis for months) are unknowingly limiting their K2's downstream effect before they even start.
Weeks 3-4: Activation
Adding MK-4 here introduces a fast-acting carboxylation signal. MK-4 is the dominant form found in brain, pancreas, and salivary gland tissue, suggesting the body preferentially routes it there. I started noticing this phase personally: during a Tuesday morning tennis session at the Presidio courts, I realized my left knee, which had been mildly stiff after hard lateral cuts, felt noticeably more fluid. I won't attribute that entirely to MK-4, but the timing aligned with the start of week three.
Weeks 5-6: Optimization
By week five, you have both sustained MK-7-driven MGP activity and MK-4's tissue-specific effects running concurrently. This is where the cardiovascular benefit is theoretically most active. MGP is the body's primary inhibitor of vascular calcification. Inadequate K2 leaves MGP in its inactive, uncarboxylated form. Weeks five and six are about sustaining that activation long enough to matter at the arterial wall level.
Weeks 7-8: Consolidation
At this point, assess your primary goal. For long-term cardiovascular and arterial health, MK-7 alone at 100-200 mcg daily is sufficient and practical. For active bone remodeling (athletes, post-menopausal women, men over 50), maintaining both forms is supported by the clinical literature. For men over 40 looking at the full picture of bone and metabolic health, I'd also recommend reviewing the best vitamins and minerals for men over 40 as a companion read.
What Can Go Wrong
Skipping the fat. Both MK-4 and MK-7 are fat-soluble. Taking them on an empty stomach or with a fat-free meal reduces absorption substantially. Always pair with a meal containing at least 10-15 grams of dietary fat.
Ignoring warfarin interactions. K2 directly affects the same clotting cascade as warfarin. Anyone on anticoagulant therapy must consult a physician before adding any K2 form. This is not a minor caution.
Under-dosing MK-4. A common mistake is buying a 45 mcg MK-4 product and expecting bone effects. The Japanese trials that demonstrated fracture reduction used 45 mg (milligrams), not micrograms, in a pharmaceutical context. For supplemental use, 1,000-1,500 mcg is a reasonable practical target. Below 500 mcg, MK-4's clinical signal is weak.
Expecting speed. Bone remodeling cycles run on months, not weeks. This 8-week protocol builds the biochemical foundation. Measurable changes in bone mineral density require 6-12 months of consistent intake.
My take: I prefer MK-7 sourced from fermented chickpea (a soy-free alternative to the traditional natto-derived MK-7) for people with soy sensitivities, and I look for products that specify the all-trans isomer of MK-7 specifically, since that's the biologically active configuration. Elm & Rye's Vitamin D3 formula pairs cleanly with a standalone K2 stack because it avoids fillers that compete with fat-soluble absorption.
The Bottom Line
MK-4 and MK-7 are not interchangeable: MK-4 acts fast and concentrates in specific tissues, while MK-7 provides sustained plasma coverage that supports arterial and systemic bone health. Used together in a structured 8-week protocol alongside adequate D3, they address the full range of K2's biological function.
FAQ
What is the difference between Vitamin K2 MK-4 and MK-7?
MK-4 has a short half-life of roughly 6-8 hours and concentrates in specific tissues like bone, brain, and pancreas. MK-7 has a half-life of approximately 72 hours, producing stable blood levels with once-daily dosing and showing stronger clinical evidence for cardiovascular and systemic bone support.
The practical implication: MK-4 requires higher doses and split dosing to be effective, while MK-7 works reliably at 100-200 mcg taken once daily with a fat-containing meal.
Can I take Vitamin K2 with Vitamin D3?
Yes, and most researchers consider co-administration preferable. Vitamin D3 upregulates production of osteocalcin and MGP, the two proteins K2 activates. Without sufficient D3, K2 has fewer target proteins to work on. Pairing them addresses both production and activation of these calcium-regulating proteins.
A typical effective combination is 2,000-5,000 IU of D3 with 100-200 mcg of MK-7, taken together with a meal containing dietary fat for optimal absorption.
How long does Vitamin K2 take to work?
For measurable improvements in carboxylated osteocalcin levels, research suggests 4-8 weeks of consistent daily dosing at 100 mcg MK-7 or higher. For bone mineral density changes, expect a minimum of 6-12 months. Vascular effects on MGP carboxylation begin within weeks but their clinical significance accumulates over longer timeframes. There is no short-term felt effect for most people, which is why consistency matters more than dose escalation.